EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An immunometabolic signature of major depressive disorder in systemic lupus erythematosus

Pierre Ellul, Nicolas Tchitchek, Grete Kvedaraviciute, Roberta Lorenzon, Isabelle Melki, Richard Delorme, Michelle Rosenzwajg, David Klatzmann

Annals of the Rheumatic Diseases · 2026-08 · 85 (8) · 1596-1609

DOI: 10.1016/j.ard.2026.02.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-08. Verfasst von Pierre Ellul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Immunology-Immunopathology- Immunotherapy (i3), INSERM, UMR_S 959, Sorbonne Université, Paris, France; Child and Adolescent Psychiatry Department, Ro…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Lupus Erythematosus, Systemic, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Systemic lupus erythematosus (SLE) frequently affects the central nervous system, leading to neuropsychiatric SLE (NPSLE). Major depressive disorder in SLE (SLEMDD) is the most frequent manifestation of NPSLE and is believed to arise from an immune-mediated process. However, biomarkers for SLEMDD remain lacking. The aim of this study was to identify candidate immunometabolic biomarkers associated with SLEMDD. METHODS: We analysed deep flow cytometry immune phenotyping, gut microbiota profiling, and targeted mass spectrometry-based metabolomics from 99 patients from the LUPIL-2 study (NCT02955615). Biological signatures were identified using unsupervised principal component analysis and supervised decision tree classification. They were then validated in an independent cohort from the TRANSIMMUNOM study (NCT02466217). RESULTS: SLEMDD patients exhibited a distinct immune profile with decreased naïve CD4⁺ T cells and naïve regulatory T cells (Tregs), alongside increased ICOS⁺ effector memory Tregs (94% classification accuracy). Gut microbiota diversity was reduced with depletion of Akkermansia muciniphila and enrichment of Faecalibacterium prausnitzii. Metabolomic analyses revealed disruptions in kynurenine and short-chain fatty acid pathways, including decreased butyrate levels. Integrative analyses demonstrated coordinated alterations linking Treg activation, microbial metabolites, and immune pathways, distinguishing SLEMDD from SLEnon-MDD with up to 85% accuracy. CONCLUSIONS: SLEMDD is associated with an immunometabolic signature involving alterations in Treg phenotype, gut microbiota composition, and metabolic pathways. These findings provide a rationale for future immunoregulatory or microbiota-targeted therapeutic strategies in SLEMDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderLupus Erythematosus, SystemicGastrointestinal MicrobiomeHumansFemaleBiomarkersMetabolomicsT-Lymphocytes, RegulatoryAdultMaleFlow CytometryMiddle AgedCD4-Positive T-Lymphocytes

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Immunology-Immunopathology- Immunotherapy (i3), INSERM, UMR_S 959, Sorbonne Université, Paris, France; Child and Adolescent Psychiatry Department, Robert Debré Hospital, Université Paris Cité, Paris, France.
  • Immunology-Immunopathology- Immunotherapy (i3), INSERM, UMR_S 959, Sorbonne Université, Paris, France.
  • Immunology-Immunopathology- Immunotherapy (i3), INSERM, UMR_S 959, Sorbonne Université, Paris, France; Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Pitié-Salpêtrière Hospital, AP-HP…
  • Department of General Pediatrics, Trousseau Hospital, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Child and Adolescent Psychiatry Department, Robert Debré Hospital, Université Paris Cité, Paris, France.

Förderung

  • French National Research Agency

Zitieren

APA

Ellul, P., Tchitchek, N., Kvedaraviciute, G., Lorenzon, R., Melki, I., Delorme, R., Rosenzwajg, M., & Klatzmann, D. (2026). An immunometabolic signature of major depressive disorder in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 85(8), 1596-1609. https://doi.org/10.1016/j.ard.2026.02.019

Vancouver

Ellul P, Tchitchek N, Kvedaraviciute G, Lorenzon R, Melki I, Delorme R, et al. An immunometabolic signature of major depressive disorder in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2026;85(8):1596-1609. doi:10.1016/j.ard.2026.02.019

BibTeX
@article{Ellul2026,
  author = {Ellul, Pierre and Tchitchek, Nicolas and Kvedaraviciute, Grete and Lorenzon, Roberta and Melki, Isabelle and Delorme, Richard and Rosenzwajg, Michelle and Klatzmann, David},
  title = {An immunometabolic signature of major depressive disorder in systemic lupus erythematosus},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {8},
  pages = {1596--1609},
  doi = {10.1016/j.ard.2026.02.019}
}
Kostenlos starten →